Drawing for KINETEK

USPTO serial 75468760

KINETEK

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
Examiner
LEIPZIG, MARC J
Law office
FILE REPOSITORY (FRANCONIA)

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with KINETEK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

PAUL W VANPEK

PAUL W VANPEK TOWNSEND AND TOWNSEND AND CREW LLP2 EMBARCADERO CTR 8TH FLSAN FRANCISCO, CA 94111-3834UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations for the treatment of diseases related to aging; pharmaceutical preparations for the treatment of diabetes, cancer, and autoimmune disorders; pharmaceutical preparations containing protein kinase or phosphatase for use as a medical diagnostic reagent; pharmaceutical preparations affecting signal transduction pathwaysACTIVE
042scientific research and laboratory services in the field of protein kinase inhibitors and effectorsACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Dec 1, 2003ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 22, 2003CNSIINQUIRY AS TO SUSPENSION MAILED
Sep 10, 2002CNSLLETTER OF SUSPENSION MAILED
Aug 14, 2002DOCKASSIGNED TO EXAMINER
Aug 13, 2002PETGPETITION TO REVIVE-GRANTED
Mar 19, 2002PETRPETITION TO REVIVE-RECEIVED
Mar 11, 2002MAILPAPER RECEIVED
Jan 7, 2002ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 16, 2001CNSIINQUIRY AS TO SUSPENSION MAILED
Sep 5, 2000CNSLLETTER OF SUSPENSION MAILED
Jun 26, 2000CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 10, 2000CNSIINQUIRY AS TO SUSPENSION MAILED
Jul 9, 1999CNSLLETTER OF SUSPENSION MAILED
Jun 17, 1999CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 16, 1998CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 15, 1998DOCKASSIGNED TO EXAMINER

Frequently asked questions

Related guidance